Frontiers in Oncology Impact Factor

In this post, apart from Frontiers in Oncology Impact Factor, I have tried to compile all the necessary information a research scholar would seek before publishing an article in the journal.

About Frontiers in Oncology Journal

Frontiers in Oncology is a highlights research in carcinogenesis and tumor progression, bridging the gap between basic research and clinical applications to advance diagnosis, personalized therapeutics and management strategies

Impact Factor Logo

Impact Factor


SJR Rank

H Index logo


Frontiers in Oncology Impact Factor

Impact Factor (IF) or often called journal impact factor (JIF) is an index provided by an analytics company named Clarivate. The impact factor is calculated by dividing the number of times the articles are cited in the last two years by the total number of publications in those two years.

  • Total Citations in 2020 and 2021 = 500
  • Total Number of Publications in 2020 and 2021 = 100
  • Impact Factor of the Journal in 2022 = 500/100 = 5

Frontiers in Oncology Impact Factor (2017-2021)

  • Frontiers in Oncology Impact Factor 2017 – 4.416
  • Frontiers in Oncology Impact Factor 2018 – 4.137
  • Frontiers in Oncology Impact Factor 2019 – 4.848
  • Frontiers in Oncology Impact Factor 2020 – 6.244
  • Frontiers in Oncology Impact Factor 2021 – 5.738 (updated 29 June 2022)

Frontiers in Oncology Impact Factor 2022

Frontiers in Oncology H-index

The h index is a metric for evaluating the cumulative impact of an author’s scholarly output and performance; measures quantity with quality by comparing publications to citations.

Journal H Index Logo

The h index of Frontiers in Oncology Journal is 102, which means among all the published articles in this journal, 102 of these publications have received at least 102 citations each.

Frontiers in Oncology Journal Metrics






Frontiers Group

Open Access


Frontiers in Oncology CiteScore

CiteScore (CS) of an academic journal is a measure reflecting the yearly average number of citations to recent articles published in that journal.

Cites / Doc. (3 years)20184.521
Cites / Doc. (3 years)20194.553
Cites / Doc. (3 years)20205.685
Cites / Doc. (3 years)20215.775
Cites / Doc. (2 years)20184.110
Cites / Doc. (2 years)20194.660
Cites / Doc. (2 years)20205.565
Cites / Doc. (2 years)20215.360

Frontiers in Oncology SCImago Rank

The SCImago Journal Rank (SJR) indicator is a measure of the scientific influence of scholarly journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where the citations come from.

Year SCImago Journal Rank (SJR)

Frontiers in Oncology Editorial Board Members

  • Field Chief Editor | Giuseppe Giaccone

A complete list of Editorial Board members can be found here

Frontiers in Oncology Publication Fee (APC)

JournalA Type ArticlesB Type ArticlesC Type ArticlesD Type Articles
Frontiers in OncologyUS$ 3,225US$ 2,020US$ 490Free

A-Type Articles: Original Research, Systematic Review, Methods, Review, Policy and Practice Reviews, Hypothesis & Theory, Technology and Code

B-Type Articles: Mini Review, Perspective, Brief Research Report

C-Type Articles: Data Report, General Commentary, Opinion

D-Type Articles: Correction, Editorial.

Frontiers in Oncology Review Time

Frontiers in Oncology prioritize rapid publication and uses single-blind peer review

Decision time immediate rejectionWithin 7 days
Duration of first review round Around 1-2 months
Accepted to publishing timeAround 32 days
Total handling time accepted manuscriptsAround 77 days

Frontiers in Oncology Reference Style

Frontiers in Oncology use Vancouver (Numbered)

Vancouver Reference Style


Sondheimer N, Lindquist S. Rnq1: an epigenetic modifier of protein function in yeast. Mol Cell (2000) 5:163-72.


Tahimic CGT, Wang Y, Bikle DD. Anabolic effects of IGF-1 signaling on the skeleton. Front Endocrinol (2013) 4:6. doi: 10.3389/fendo.2013.00006


Sorenson PW, Caprio JC. “Chemoreception,”. In: Evans DH, editor. The Physiology of Fishes. Boca Raton, FL: CRC Press (1998). p. 375-405.


Cowan WM, Jessell TM, Zipursky SL. Molecular and Cellular Approaches to Neural Development. New York: Oxford University Press (1997). 345 p.


Christensen S, Oppacher F. An analysis of Koza’s computational effort statistic for genetic programming. In: Foster JA, editor. Genetic Programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3–5; Kinsdale, Ireland. Berlin: Springer (2002). p. 182–91.


World Health Organization. E. coli (2018). [Accessed March 15, 2018].


Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible Endoscopic Grasping and Cutting Device and Positioning Tool Assembly. United States patent US 20020103498 (2002).


Perdiguero P, Venturas M, Cervera MT, Gil L, Collada C. Data from: Massive sequencing of Ulms minor’s transcriptome provides new molecular tools for a genus under the constant threat of Dutch elm disease. Dryad Digital Repository. (2015)


Smith, J. (2008) Post-structuralist discourse relative to phenomological pursuits in the deconstructivist arena. [dissertation/master’s thesis]. [Chicago (IL)]: University of Chicago


Smith, J. Title of the document. Preprint repository name [Preprint] (2008). Available at: https://persistent-url (Accessed March 15, 2018).

Frontiers in Oncology Reference Style

You can download the Vancouver style here – Frontiers in Oncology Endnote Style and Frontiers in Oncology Zotero Style

Frontiers in Oncology Abbreviation

The ISO 4 standard abbreviation for abstracting, indexing, and referencing purposes of Frontiers in Oncology isFront Oncol

Frontiers in Oncology Acceptance Rate

The acceptance rate of a journal is the ratio of the number of articles submitted to the number of articles published.

The acceptance rate for 2021 was on average 60% across all Frontiers journals and as low as 21% in some journals.

Frontiers in Oncology Indexed in

Science is indexed in Scopus, SCImago, Web of Science, and UGC journal ranking

Web of Science logo

Read More

Similar Posts